Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stok Raporu

Piyasa değeri: UK£15.0m

Hemogenyx Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Vladislav Sandler

İcra Kurulu Başkanı

UK£397.0k

Toplam tazminat

CEO maaş yüzdesi98.0%
CEO görev süresi10.9yrs
CEO sahipliği3.0%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi7.1yrs

Son yönetim güncellemeleri

Recent updates

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Aug 21
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

May 04
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Jan 06
We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Oct 09
Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

CEO Tazminat Analizi

Vladislav Sandler'un ücretlendirmesi Hemogenyx Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-UK£5m

Mar 31 2024n/an/a

-UK£6m

Dec 31 2023UK£397kUK£389k

-UK£7m

Sep 30 2023n/an/a

-UK£7m

Jun 30 2023n/an/a

-UK£7m

Mar 31 2023n/an/a

-UK£6m

Dec 31 2022UK£282kUK£276k

-UK£4m

Sep 30 2022n/an/a

-UK£3m

Jun 30 2022n/an/a

-UK£3m

Mar 31 2022n/an/a

-UK£4m

Dec 31 2021UK£213kUK£206k

-UK£5m

Sep 30 2021n/an/a

-UK£5m

Jun 30 2021n/an/a

-UK£5m

Mar 31 2021n/an/a

-UK£3m

Dec 31 2020UK£205kUK£200k

-UK£2m

Sep 30 2020n/an/a

-UK£2m

Jun 30 2020n/an/a

-UK£2m

Mar 31 2020n/an/a

-UK£2m

Dec 31 2019UK£149kUK£145k

-UK£1m

Sep 30 2019n/an/a

-UK£2m

Jun 30 2019n/an/a

-UK£2m

Mar 31 2019n/an/a

-UK£2m

Dec 31 2018UK£98kUK£94k

-UK£2m

Sep 30 2018n/an/a

-UK£2m

Jun 30 2018n/an/a

-UK£3m

Mar 31 2018n/an/a

-UK£3m

Dec 31 2017UK£79kUK£79k

-UK£2m

Tazminat ve Piyasa: Vladislav 'nin toplam tazminatı ($USD 503.23K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 353.74K ).

Tazminat ve Kazançlar: Vladislav şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Vladislav Sandler (59 yo)

10.9yrs

Görev süresi

UK£397,000

Tazminat

Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Vladislav Sandler
Co-Founder7.1yrsUK£397.00k2.96%
£ 444.5k
Alexis Sandler
Independent Co-Founder & Non-Executive Director7.1yrsUK£60.00k5.36%
£ 803.5k
Koen Van Besien
Clinical Advisor & Medical Directorno dataVeri yokVeri yok
H. Shepard
Member of Scientific Advisory Board6.7yrsVeri yokVeri yok
Peter Redmond
Independent Non-Executive Director9.3yrsUK£50.00k0.40%
£ 59.9k
Marc Feldmann
Independent Chairman & Chairman of Advisory Board7.2yrsUK£15.00kVeri yok

7.1yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HEMO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).